

11 September 2014

ASX ANNOUNCEMENT

APPOINTMENT OF VICE PRESIDENT OF CLINICAL RESEARCH

Actinogen Ltd, an Australian biotechnology company, is pleased to announce the appointment of Mr Vincent Ruffles as Vice President of Clinical Research. Mr Ruffles will be a member of Actinogen's executive management team and will be responsible for providing the overall strategy, scientific and regulatory oversight and direction of clinical programs of UE2343.

Mr Ruffles has nearly 20 years of experience in the pharmaceutical and biotechnology industries, and brings a wealth of knowledge in working across all phases of the drug development cycle. He began his career in the UK at Hoechst-Roussel (now Sanofi) and then lived and worked in Geneva, Switzerland for Serono (now Merck Serono). After returning to the UK to work at Procter & Gamble and then Amgen, Vincent moved to Sydney, Australia in 2008 where he currently lives with his wife and family.

He has worked across several blockbuster drugs taking them through clinical development and has extensive experience in Alzheimer's disease and related therapeutic areas. Vincent's recent role in a global Contract Research Organisation gave him great exposure to the Asia Pacific region and a variety of client companies and their needs. This experience included local start-up pharmaceutical companies with limited resources but significant potential and multinational clients who did not have a local entity or understanding of the region. His experience includes timely, within budget delivery of study site activation as well as ongoing oversight and reporting of project progress. Vincent's excellent leadership and communication skills with stakeholders including healthcare professionals will be a considerable asset to the company.

"We are delighted to have Vincent as part of our team. His strong and highly relevant experience in initiating and conducting clinical studies will be pivotal to advance the clinical program of UE2343 in Dementia" said Dr Brendan de Kauwe, Executive Chairman of Actinogen.

As part of his remuneration package Mr Ruffles will be issued 2,000,000 loan plan shares at an issue price of 2 cents each, to vest in three years from the date of commencement of Employment. The issue of the shares will be subject to shareholder approval at the upcoming general meeting.

-end-

Dr Brendan de Kauwe
Executive Chairman
Actinogen Limited

About Actinogen Limited Actinogen Limited (ASX: ACW)

Actinogen is a clinical stage Australian biotechnology company focused on the development of novel treatments for Alzheimer's Disease (AD) and other major age-related neurodegenerative disorders. Actinogen's lead candidate UE2343 is a small molecule inhibitor of 11-beta-hydroxysteroid dehydrogenase (11 β -HSD1) an enzyme that reduces cortisone to the active hormone cortisol that activates glucocorticoid receptors. There is evidence for a role of glucocorticoids and hypothalamus-pituitary-adrenal axis dysfunction in AD that includes both cortisol-induced neurotoxicity on the hippocampal formation and acute ongoing impairment of cognition. UE2343 was discovered in 2007 at the laboratory of Professor Brian Walker at the University of Edinburgh. Subsequently, the University received significant support from the Wellcome Trust's Seeding Drug Discovery program to advance UE2343 into early clinical development.

In addition, the company has an early stage drug discovery program focused on developing drugs to treat brain cancer and potentially other oncological diseases by the targeted killing of cancer stem cells (CSCs). The first study was conducted in collaboration with Curtin University and the results demonstrated substantial reduction of proliferation in CSCs populations in glioblastoma cell lines.